Author

Krisztina Barbara Gecse

Intestinal ultrasound: The optimal tool for tight monitoring in IBD?
Intestinal ultrasound: The optimal tool for tight monitoring in IBD?

Krisztina Barbara Gecse

Biologicals in UC: Which and when to use?
Biologicals in UC: Which and when to use?

Krisztina Barbara Gecse

Webinar | Positioning Treatments in IBD
Webinar | Positioning Treatments in IBD

Krisztina Barbara Gecse  et al.

EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE
EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE

Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)
Revolutionizing the treatment landscape in Crohn’s disease: How IL-23 and JAK inhibitors are changing the rhythm (AbbVie) (Complete Session)

Krisztina Barbara Gecse  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Krisztina Barbara Gecse  et al.

RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM

Krisztina Barbara Gecse  et al.

SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES
SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES

Krisztina Barbara Gecse  et al.

IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
IMPACT OF 8 WEEKS TOFACITINIB TREATMENT ON HISTOLOGICAL INFLAMMATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Krisztina Barbara Gecse  et al.

INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS
INTESTINAL ULTRASOUND INSTEAD OF ENDOSCOPY: LARGE POTENTIAL ROLE AND COST SAVINGS

Krisztina Barbara Gecse  et al.

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Krisztina Barbara Gecse  et al.

CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL
CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL

Krisztina Barbara Gecse  et al.

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Krisztina Barbara Gecse  et al.

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS
REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Krisztina Barbara Gecse  et al.

THE DIAGNOSTIC PERFORMANCE OF A TRAINED PHYSICIAN VS. A PEDIATRIC RADIOLOGIST IN PERFORMING AN INTESTINAL ULTRASOUND IN CHILDREN WITH IBD
THE DIAGNOSTIC PERFORMANCE OF A TRAINED PHYSICIAN VS. A PEDIATRIC RADIOLOGIST IN PERFORMING AN INTESTINAL ULTRASOUND IN CHILDREN WITH IBD

Krisztina Barbara Gecse  et al.

BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
BASELINE HYPERTROPHY OF THE SUBMUCOSA AT INTESTINAL ULTRASOUND PREDICTS FAILURE OF TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Krisztina Barbara Gecse  et al.

EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE
EVALUATION OF THE EFFICACY OF TOFACITINIB AS MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY OCTAVE SUSTAIN BASELINE ENDOSCOPIC SUBSCORE

Krisztina Barbara Gecse  et al.

EARLY PREDICTORS OF SURGERY IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: RESULTS OF AN INTERNATIONAL COHORT STUDY
EARLY PREDICTORS OF SURGERY IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS: RESULTS OF AN INTERNATIONAL COHORT STUDY

Krisztina Barbara Gecse  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Krisztina Barbara Gecse  et al.

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

Krisztina Barbara Gecse  et al.

Item 1 - 20 / 25
1
2